血管移植物及腔内移植物感染的治疗与随访:德尔菲共识
该德尔菲共识针对血管移植物或腔内移植物感染(VGEI)的抗菌治疗、手术管理和随访形成专家推荐。专家组就经验性抗菌治疗启动时机、不同部位VGEI的初始覆盖策略及术后疗程个体化达成共识,强调多学科框架下基于微生物学信息的个体化治疗。
要点
- 经验性抗菌治疗仅用于脓毒症、出血等并发症或诊断干预延迟时。
- 腹主动脉VGEI无肠瘘且病原未知时,初始覆盖革兰阳性球菌、革兰阴性杆菌和厌氧菌。
- 胸主动脉VGEI无瘘时优先覆盖革兰阳性菌,可选MRSA覆盖。
核心结论
- 该共识为VGEI管理提供实用的、基于专家的抗菌治疗指导,强调多学科框架下个体化、基于微生物学信息的治疗。
研究设计与样本
- 采用改良德尔菲法,由感染病学、血管与心胸外科、微生物学和核医学专家参与四轮调查。
- 采用Cronbach's alpha评估轮次间内部一致性,阈值>0.80。
主要发现
- 专家组同意经验性抗菌治疗仅用于出现并发症(如脓毒症和出血)或诊断干预延迟的患者。
- 经验性治疗须根据移植物位置和危险因素个体化。
- 腹主动脉VGEI无肠瘘且病原未知时,初始覆盖应针对革兰阳性球菌、革兰阴性杆菌和厌氧菌,并根据风险考虑MRSA/MRSE覆盖。
- 胸主动脉VGEI无瘘时优先革兰阳性覆盖,可选MRSA覆盖。
- 术后疗程应个体化;完全移除移植物并以自体静脉替换后推荐6周抗菌疗程,若有生物利用度好的口服选项可早期口服转换。
关键数值与推荐
- 声明≥75%同意(同意/强烈同意)视为达成共识。
- Cronbach's alpha>0.80用于评估轮次间内部一致性。
- 完全移除移植物并以自体静脉替换后:推荐6周抗菌疗程,可早期口服转换。
- 残留人工材料时:推荐至少4–6周静脉治疗后口服,总疗程12周。
- 毒力病原体、感染源控制不完全或炎症标志物持续存在时考虑延长治疗。
临床怎么用
- 经验性抗菌治疗应限制用于并发症或诊断延迟的患者,并根据移植物位置和危险因素个体化。
- 腹主动脉VGEI无肠瘘且病原未知时,初始覆盖革兰阳性球菌、革兰阴性杆菌和厌氧菌,并按风险考虑MRSA/MRSE。
- 胸主动脉VGEI无瘘时优先革兰阳性覆盖,可选MRSA覆盖。
- 完全移除移植物并以自体静脉替换后可给予6周抗菌疗程,并尽早口服转换。
- 残留人工材料时给予至少4–6周静脉治疗后口服,总疗程12周,特定情况延长。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
SCOPE: Vascular graft or endograft infection (VGEI) is a severe complication requiring a multidisciplinary approach combining surgery and antimicrobial therapy. This study aimed to develop expert consensus on the management and follow-up of VGEI, with a focus on antimicrobial strategies. METHODS: A modified Delphi method was conducted to reach consensus on key aspects of VGEI care, including antimicrobial treatment, surgical management, and follow-up. An expert panel representing infectious diseases, vascular and cardiothoracic surgery, microbiology, and nuclear medicine participated in four rounds of surveys. Ten general and 35 specific statements were rated using a five-point Likert scale. Statements with ≥75% agreement (agree/strongly agree) were considered to have achieved consensus. Internal consistency across rounds was assessed using Cronbach's alpha (>0.80). QUESTIONS ADDRESSED BY THE DELPHI METHOD AND RECOMMENDATIONS: The panel agreed that empirical antimicrobial therapy should be initiated only in patients with complications (e.g. sepsis and bleeding) or when diagnostic intervention is delayed. Empirical therapy must be individualized based on graft location and risk factors. For abdominal VGEI without aorto-enteric fistula and unknown pathogens, initial coverage should target gram-positive cocci, gram-negative bacilli, and anaerobes, with consideration for Methicillin-Resistant Staphylococcus aureus (MRSA)/Methicillin-Resistant Staphylococcus epidermidis (MRSE) based on risk. For thoracic VGEI without fistula, gram-positive coverage is prioritized, with optional MRSA coverage. Postoperative treatment duration should be individualized. In cases of complete graft removal and replacement with autologous veins, a 6-week antibiotic course is recommended, with early oral switch if bioavailable options are available. If prosthetic material remains, at least 4 to 6 weeks of intravenous therapy followed by oral treatment for a total of 12 weeks is advised. Prolonged therapy should be considered in cases with virulent pathogens, incomplete source control, or persistent inflammatory markers. The study provides practical, expert-based antimicrobial guidance for VGEI management and emphasizes the importance of individualized, microbiologically informed therapy within a multidisciplinary care framework.
引用
- Kouijzer IJE, Hernández-Meneses M, Aarntzen EHJG, et al. Treatment and follow-up of vascular graft and endograft infection: Delphi consensus document. Clin Microbiol Infect. 2025. PMID: 40744275. doi:10.1016/j.cmi.2025.07.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。